Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
Notified -
Globe Newswire28-04-2025, 20:23
SL Green Realty Corp. to Participate in the 2023 Citi 17-02-2023, 04:12